Controversial Alzheimers drug could cost US $334B—nearly half of DoD budget – Ars Technica

Enlarge/ Pedestrians walk past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Biogen Inc. shares soared after its controversial Alzheimer’s disease therapy was approve… [+4095 chars]